Developing Psychedelic Medicine Beyond What We Already Know!
VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
News
Levitee Labs Announces Gold Sponsorship of Wonderland Psychedelic Conference in Miami
Levitee Labs will be a Gold Sponsor and VIP Lounge Sponsor at the world’s largest psychedelic medicine conference If you...
Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing...
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
– Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts – – Advancing...
Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)
Company announcement – No. 66/ 2021 Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development...
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing...
InflaRx Reports Third Quarter 2021 Financial & Operating Results
Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for...
Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
Company Ended the Quarter With Cash of Approximately $559 MillionNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:...
Repligen Releases Inaugural Sustainability Report
Sets Baseline and Provides SASB, GRI Core and SDG DisclosuresWALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:...
KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD
Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization...
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
A Technosphere® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions...
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company...
EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
-- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of DirectorsSOUTH SAN FRANCISCO,...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021
DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired...
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)
Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic...
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and...
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health OrganizationPediatric EUA submission based on immuno-bridging clinical trial...
Release date of nine-month interim report (Q3) 2021 for ALK and audio cast
On Thursday, 11 November 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its nine-month interim report...
